{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:34:57Z","timestamp":1777419297751,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To present the pharmacology and pharmacokinetics of nelarabine, 9-\u03b2-D-arabinofuranosylguanine (ara-G) and intraleukemic cellular pharmacokinetics of 9-\u03b2-D-arabinofuranosylguanine triphosphate (ara-GTP) generated from the administration of nelarabine, and clinical and safety information relative to nelarabine use in the treatment of hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>MEDLINE (1966\u2014December 2004) was searched using the English-language key terms 2-amino-6-methoxypurine arabinoside, 506U78, and nelarabine. Data were also obtained from published abstracts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Clinical studies evaluating the pharmacokinetics of nelarabine, ara-G, and cellular ara-GTP and use of nelarabine, alone or in combination with other agents for the treatment of hematologic malignancies, were included in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>\n                      Nelarabine is the water-soluble, 6-methoxy analog of 9-\u03b2-D-ara-G. Nelarabine is readily converted to ara-G by endogenous adenosine deaminase. The half-life of nelarabine is approximately 15 minutes compared with 2\u20134 hours for ara-G. The clearance of ara-G is higher in children than in adults (0.312 vs 0.213 L \u00d7 h\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00d7 kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      ). Intracellular ara-GTP elimination is slow relative to nelarabine and ara-G. In pediatric and adult patients, neurologic toxicity is dose limiting. Severe myelosuppression was not consistently observed. Major responses were seen in patients with T-cell malignancies. Patients who responded had significantly higher intracellular ara-GTP concentrations compared with those who did not respond.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Nelarabine is an effective ara-G prodrug. Nelarabine has significant activity against malignant T-cells and appears to be an important addition to treatments of various leukemias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1e453","type":"journal-article","created":{"date-parts":[[2005,5,3]],"date-time":"2005-05-03T22:29:51Z","timestamp":1115159391000},"page":"1056-1063","source":"Crossref","is-referenced-by-count":13,"title":["Nelarabine: A Nucleoside Analog with Efficacy in T-Cell and other Leukemias"],"prefix":"10.1177","volume":"39","author":[{"given":"David F","family":"Kisor","sequence":"first","affiliation":[{"name":"David F Kisor BS PharmD, Associate Professor of Pharmacokinetics, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810-6000, fax 419\/772-1917"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,6,1]]},"reference":[{"key":"bibr1-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6215(00)80531-5"},{"key":"bibr2-aph.1E453","first-page":"3352","volume":"55","author":"Lambe CU","year":"1995","journal-title":"Cancer Res"},{"key":"bibr3-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1021\/bi00889a004"},{"key":"bibr4-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.679"},{"key":"bibr5-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.17.1416"},{"key":"bibr6-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.19.19"},{"key":"bibr7-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"bibr8-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)39698-X"},{"key":"bibr9-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)70512-2"},{"key":"bibr10-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)46267-3"},{"key":"bibr11-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685844"},{"key":"bibr12-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3607"},{"key":"bibr13-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2142"},{"key":"bibr14-aph.1E453","unstructured":"Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, A phase I study of 2-amino-9-beta-D-arabinofuranosyl-6-methoxy-9Hpurine (506U78[Nelarabine]) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol (in press)."},{"key":"bibr15-aph.1E453","first-page":"1817","volume":"50","author":"Prus KL","year":"1990","journal-title":"Cancer Res"},{"key":"bibr16-aph.1E453","first-page":"4937","volume":"59","author":"Rodriguez CO","year":"1999","journal-title":"Cancer Res"},{"key":"bibr17-aph.1E453","first-page":"3000","volume":"62","author":"Rodriguez CO","year":"2002","journal-title":"Cancer Res"},{"key":"bibr18-aph.1E453","first-page":"2107","volume":"3","author":"Rodriguez COR","year":"1997","journal-title":"Clin Cancer Res"},{"key":"bibr19-aph.1E453","first-page":"4673","volume":"39","author":"Ono K","year":"1979","journal-title":"Cancer Res"},{"key":"bibr20-aph.1E453","first-page":"1517","volume":"55","author":"Gandhi V","year":"1995","journal-title":"Cancer Res"},{"key":"bibr21-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.10.5011"},{"key":"bibr22-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.76.5.2430"},{"key":"bibr23-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-1248-2_29"},{"key":"bibr24-aph.1E453","first-page":"1008","volume":"45","author":"Shewach DS","year":"1985","journal-title":"Cancer Res"},{"key":"bibr25-aph.1E453","first-page":"3646","volume":"45","author":"Verhoef V","year":"1985","journal-title":"Cancer Res"},{"key":"bibr26-aph.1E453","first-page":"6498","volume":"49","author":"Shewach DS","year":"1989","journal-title":"Cancer Res"},{"key":"bibr27-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.995"},{"key":"bibr28-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90127-5"},{"key":"bibr29-aph.1E453","first-page":"329","volume":"48","author":"Gandhi V","year":"1988","journal-title":"Cancer Res"},{"key":"bibr30-aph.1E453","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309147356"},{"key":"bibr31-aph.1E453","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2002-06-1713","volume":"100","author":"DeAngelo DJ","year":"2002","journal-title":"Blood"},{"key":"bibr32-aph.1E453","first-page":"4757","volume":"100","author":"Goy A","year":"2002","journal-title":"Blood"},{"key":"bibr33-aph.1E453","first-page":"792","volume":"102","author":"Berg SL","year":"2003","journal-title":"Blood"},{"key":"bibr34-aph.1E453","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012096510125"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1E453","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1E453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:10:16Z","timestamp":1777374616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1E453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1345\/aph.1E453"],"URL":"https:\/\/doi.org\/10.1345\/aph.1e453","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}